1. Home
  2. GCV vs GANX Comparison

GCV vs GANX Comparison

Compare GCV & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Convertible and Income Securities Fund Inc. (The)

GCV

Gabelli Convertible and Income Securities Fund Inc. (The)

HOLD

Current Price

$4.56

Market Cap

91.2M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.78

Market Cap

78.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCV
GANX
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.2M
78.2M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
GCV
GANX
Price
$4.56
$1.78
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
60.8K
507.4K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.63
$1.41
52 Week High
$4.62
$4.34

Technical Indicators

Market Signals
Indicator
GCV
GANX
Relative Strength Index (RSI) 56.23 46.62
Support Level $3.98 $1.73
Resistance Level $4.62 $2.09
Average True Range (ATR) 0.08 0.10
MACD -0.01 -0.00
Stochastic Oscillator 78.57 62.50

Price Performance

Historical Comparison
GCV
GANX

About GCV Gabelli Convertible and Income Securities Fund Inc. (The)

GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive, and others. All the operation of the group is operated through the regions of the United States.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: